BRAIN Biotech Past Earnings Performance
Past criteria checks 0/6
BRAIN Biotech has been growing earnings at an average annual rate of 7.4%, while the Chemicals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 10.6% per year.
Key information
7.4%
Earnings growth rate
11.6%
EPS growth rate
| Chemicals Industry Growth | 4.3% |
| Revenue growth rate | 10.6% |
| Return on equity | -24.3% |
| Net Margin | -17.3% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BRAIN Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 48 | -8 | 22 | 0 |
| 31 Mar 22 | 44 | -8 | 21 | 0 |
| 31 Dec 21 | 41 | -4 | 21 | 0 |
| 30 Sep 21 | 39 | -5 | 21 | 0 |
| 30 Jun 21 | 37 | -6 | 20 | 0 |
| 31 Mar 21 | 37 | -6 | 20 | 0 |
| 31 Dec 20 | 37 | -11 | 19 | 0 |
| 30 Sep 20 | 39 | -10 | 19 | 0 |
| 30 Jun 20 | 41 | -9 | 20 | 0 |
| 31 Mar 20 | 41 | -12 | 19 | 0 |
| 31 Dec 19 | 41 | -12 | 19 | 0 |
| 30 Sep 19 | 40 | -11 | 19 | 0 |
| 30 Jun 19 | 39 | -9 | 19 | 0 |
| 31 Mar 19 | 37 | -7 | 18 | 0 |
| 31 Dec 18 | 33 | -7 | 17 | 0 |
| 30 Sep 18 | 29 | -8 | 16 | 0 |
| 30 Jun 18 | 27 | -9 | 18 | 0 |
| 31 Mar 18 | 25 | -8 | 17 | 0 |
| 31 Dec 17 | 26 | -7 | 15 | 0 |
| 30 Sep 17 | 26 | -10 | 18 | 0 |
| 30 Jun 17 | 26 | -14 | 19 | 0 |
| 31 Mar 17 | 26 | -14 | 19 | 0 |
| 31 Dec 16 | 25 | -17 | 22 | 0 |
| 30 Sep 16 | 25 | -15 | 19 | 0 |
| 30 Jun 16 | 24 | -10 | 14 | 0 |
| 31 Mar 16 | 24 | -9 | 13 | 0 |
| 31 Dec 15 | 24 | -7 | 13 | 0 |
Quality Earnings: BNND is currently unprofitable.
Growing Profit Margin: BNND is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNND is unprofitable, but has reduced losses over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare BNND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNND is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-18.4%).
Return on Equity
High ROE: BNND has a negative Return on Equity (-24.3%), as it is currently unprofitable.